At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease.

Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease.

To learn more please visit www.hookipapharma.com. 


Biotechnology

Life Sciences

Pharmaceutical

HOOKIPA Pharma Inc.

Klaus Orlinger

Reinhard Kandera

Roland Bauer

Mark McKechnie

Roman Necina

Reischer Nicolas

Susan Trinker

The Leadership Team at HOOKIPA Pharma Inc. consists of key executives responsible for strategic decision-making and guiding the company’s mission to develop innovative immunotherapies. This team includes experts across various domains such as scientific research, finance, operations, legal matters, and business development, united to drive the company’s goal of eradicating cancers and infectious diseases through cutting-edge therapeutic solutions.

Leadership Team

Quality and Supply Chain Team

Research and Development

Leadership Team

About

Team members

Other teams at HOOKIPA Pharma Inc.

Quality and Supply Chain Team

Research and Development